

ASX Announcement

14 October 2022

Non-Executive Director Retirement

Antisense Therapeutics Limited [ASX:ANP | US OTC:ATHJY | FSE:AWY], (the Company) wishes to advise that Non-Executive Director of the Company, Dr Gary Pace, has confirmed his intention to retire this year from the Board of Directors. After seven years as a director, Dr Pace was due to stand for re-election at the upcoming 2022 Annual General Meeting of shareholders and accordingly will not seek re-election. As a result of this decision, Dr Pace will retire from the Board at the conclusion of the 2022 Annual General Meeting, scheduled for 17 November 2022.

Dr Pace has served the Company as a Non-Executive Director since 2015 and is currently Governance and Nomination Chair, Remuneration Committee Member, Audit & Risk Committee Member.

Antisense Therapeutics CEO and MD Mark Diamond said "I would like to thank Gary for his stewardship and service during his tenure at ANP in which time the Company successfully advanced its program in Duchenne muscular dystrophy from concept to advanced stage clinical development. Gary's extensive corporate experience, particularly in governance, has been an important asset to the Board and the Company."

Antisense Therapeutics Chair Dr Charmaine Gittleson paid tribute to Dr Pace, praising his leadership and contribution to company strategy, most notably in re-shaping the clinical development plan for ATL1102 in light of recent market conditions. Dr Gittleson said "Gary leaves Antisense therapeutics with a strong forward plan and I thank him for his commitment, counsel and support. He has played an important role in shaping the governance culture of the organisation and his overall deep experience in biotech has been valuable in addressing both challenges and opportunities. The Board thanks him for his contribution and services over the past seven years and wishes him well in his ongoing and future endeavours."

For more information please contact:

Antisense Therapeutics

Mark Diamond
Managing Director
+61 (0)3 9827 8999
www.antisense.com.au

Investment Enquiries

Gennadi Koutchin
XEC Partners
gkoutchin@xecpartners.com.au
1300 932 037

US/European IR & Media

Laine Yonker/Joe Green
Edison Investor Relations
lyonker@edisongroup.com
+1 646-653-7035

This announcement has been authorised for release by the Managing Director.

About Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.